Literature DB >> 23688424

Genetic deletion of Cxcl14 in mice alters uterine NK cells.

Qichen Cao1, Hua Chen, Zhili Deng, Jingwen Yue, Qi Chen, Yujing Cao, Lina Ning, Xiaohua Lei, Enkui Duan.   

Abstract

The uterine natural killer cells (uNK cells) are the major immune cells in pregnant uterus and the number of uNK cells is dramatically increased during placentation and embryo development. The uNK cells are necessary for the immune tolerance, cytokine secretion and angiogenesis of placenta. Former studies indicated that the population expansion of uNK cells was accomplished through recruitment of NK cell precursors from the spleen and bone marrow, but not proliferation of NK cells. However, the necessary molecules within this process were little understood. Here in our study, we found the co-localized expression of Cxcl14 protein with uNK cells in E13.5 pregnant uterus. Moreover, we used Cxcl14 knockout mice to examine uNK cells in mesometrial lymphoid aggregate of pregnancy (MLAp) and decidua basalis (DB) of E13.5 pregnant uterus and found significantly decreased uNK cells in Cxcl14(-/-) pregnant uteri compared with Cxcl14(+/-) pregnant uteri. To further explorer the molecular change in MLAp and DB after Cxcl14 knockout, we isolated the MLAp and DB from Cxcl14(+/+) and Cxcl14(-/-) pregnant uteri and performed microarray analysis. We found many genes were up and down regulated after Cxcl14 knockout. In conclusion, our results suggested the important function of Cxcl14 in uNK cells and the proper level of Cxcl14 protein were required to recruit NK cells to pregnant uterus. Crown
Copyright © 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23688424     DOI: 10.1016/j.bbrc.2013.04.106

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  Leukocyte driven-decidual angiogenesis in early pregnancy.

Authors:  Patricia D A Lima; Jianhong Zhang; Caroline Dunk; Stephen J Lye; B Anne Croy
Journal:  Cell Mol Immunol       Date:  2014-07-28       Impact factor: 11.530

Review 2.  The multifarious roles of the chemokine CXCL14 in cancer progression and immune responses.

Authors:  Joseph A Westrich; Daniel W Vermeer; Paul L Colbert; William C Spanos; Dohun Pyeon
Journal:  Mol Carcinog       Date:  2020-03-24       Impact factor: 4.784

3.  Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma.

Authors:  T Kondo; S Ozawa; T Ikoma; X-Y Yang; K Kanamori; K Suzuki; H Iwabuchi; Y Maehata; C Miyamoto; T Taguchi; T Kiyono; E Kubota; R-I Hata
Journal:  Oncogenesis       Date:  2016-07-11       Impact factor: 7.485

4.  Integrated Analysis of Multiple Microarrays Based on Raw Data Identified Novel Gene Signatures in Recurrent Implantation Failure.

Authors:  Hong Zeng; Yu Fu; Lang Shen; Song Quan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-07       Impact factor: 5.555

5.  Spatial transcriptomics analysis of uterine gene expression in enhancer of zeste homolog 2 conditional knockout mice†.

Authors:  Ana M Mesa; Jiude Mao; Theresa I Medrano; Nathan J Bivens; Alexander Jurkevich; Geetu Tuteja; Paul S Cooke; Cheryl S Rosenfeld
Journal:  Biol Reprod       Date:  2021-11-15       Impact factor: 4.161

Review 6.  CXCL14 as an emerging immune and inflammatory modulator.

Authors:  Jing Lu; Mita Chatterjee; Hannes Schmid; Sandra Beck; Meinrad Gawaz
Journal:  J Inflamm (Lond)       Date:  2016-01-05       Impact factor: 4.981

7.  CXCL14: the Swiss army knife chemokine.

Authors:  Charaf Benarafa; Marlene Wolf
Journal:  Oncotarget       Date:  2015-10-27

8.  Suppression of Antitumor Immune Responses by Human Papillomavirus through Epigenetic Downregulation of CXCL14.

Authors:  Louis Cicchini; Joseph A Westrich; Tao Xu; Daniel W Vermeer; Jennifer N Berger; Eric T Clambey; Denis Lee; John I Song; Paul F Lambert; Robert O Greer; John H Lee; Dohun Pyeon
Journal:  MBio       Date:  2016-05-03       Impact factor: 7.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.